Thursday, May 07, 2020 The IND216 trial: Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia, has been permanently closed. About the trial: Buparlisib has been shown to shrink tumours in animals. It has been studied in some people and seems promising but it is not clear if it can offer better results than standard treatment. The standard or usual treatment for this disease is chemotherapy, targeted therapy or radiation, either alone or in combination. For more information please visit the CCTG IND216 trial page.
